Boehringer Ingelheim Launches SCOVELLA in Great Britain, the First Approved Therapy for Insulin Dysregulation in Horses, a Main Cause of Laminitis
September 02, 2026
September 02, 2026
INGELHEIM AM RHEIN, Germany, Sept. 2 -- Boehringer Ingelheim, a pharmaceutical company, issued the following news release:
* * *
Boehringer Ingelheim launches SCOVELLA(R) in Great Britain, the first approved therapy for insulin dysregulation in horses, a main cause of laminitis
* SCOVELLA(R) is the first therapy specifically developed and approved for the treatment of hyperinsulinemia in insulin-dysregulated horses and ponies/1, targeting the key underlying . . .
* * *
Boehringer Ingelheim launches SCOVELLA(R) in Great Britain, the first approved therapy for insulin dysregulation in horses, a main cause of laminitis
* SCOVELLA(R) is the first therapy specifically developed and approved for the treatment of hyperinsulinemia in insulin-dysregulated horses and ponies/1, targeting the key underlying . . .